REFERENCES
1. Murteira S, Ghezaiel Z, Karray S, Lamure M. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature. J Mark Access Health Policy. 2013;1:21131.
3. Galindez G, Matschinske J, Rose TD, et al. Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nat Comput Sci. 2021;1:33-41.
4. European Medicines Agency. Orphan medicinal product designation 2000-2020. Available from: https://www.ema.europa.eu/en/documents/other/orphan-medicines-figures-2000-2020_en.pdf [Last accessed on 7 Apr 2023].
5. European Medicines Agency. Support for development of orphan medicines. Available from: https://www.ema.europa.eu/en/documents/report/report-workshop-support-orphan-medicines-development_en.pdf [Last accessed on 7 Apr 2023].
6. Southall NT, Natarajan M, Lau LPL, et al. IRDiRC Data Mining and Repurposing Task Force. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force. Orphanet J Rare Dis. 2019;14:225.
7. Begley CG, Ashton M, Baell J, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med. 2021;13:eabd5524.
8. Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci. 2014;10:654-63.
9. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689-702.
10. Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020;72:1145-51.
11. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag. 2006;2:411-22.
12. Roy S, Kloner RA, Salloum FN, Jovin IS. Cardiac effects of phosphodiesterase-5 inhibitors: efficacy and safety. Cardiovasc Drugs Ther. ; doi: 10.1007/s10557-021-07275-y. 2021;Online ahead of print.
13. Pan Y, Cheng T, Wang Y, Bryant SH. Pathway analysis for drug repositioning based on public database mining. J Chem Inf Model. 2014;54:407-18.
14. Pagliazzi A, Oranges T, Traficante G, et al. PIK3CA-related overgrowth spectrum from diagnosis to targeted therapy: a case of CLOVES syndrome treated with Alpelisib. Front Pediatr. 2021;9:732836.
15. Scherman D, Fetro C. Drug repositioning for rare diseases: knowledge-based success stories. Therapie. 2020;75:161-7.
16. Chang DY, Ma WL, Lu YS. Role of Alpelisib in the treatment of PIK3CA-mutated breast cancer: patient selection and clinical perspectives. Ther Clin Risk Manag. 2021;17:193-207.
17. Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. 2018;24:856-70.
18. Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558:540-6.
19. Canaud G, Gutiérrez JCL, Irvine A, et al. LBA23 EPIK-P1: retrospective chart review study of patients (pts) with PIK3CA-related Overgrowth Spectrum (PROS) who have received alpelisib (ALP) as part of a compassionate use programme. Ann Oncol. 2021;32:S1297.
20. Rosenblatt M. How academia and the pharmaceutical industry can work together: the president’s lecture, annual meeting of the American Thoracic Society, San Francisco, California. Ann Am Thorac Soc. 2013;10:31-8.
21. den Berg S, de Visser S, Leufkens HGM, Hollak CEM. Drug repurposing for rare diseases: a role for academia. Front Pharmacol. 2021;12:746987.
22. Hernandez JJ, Pryszlak M, Smith L, et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol. 2017;7:273.
23. Fetro C, Scherman D. Drug repurposing in rare diseases: myths and reality. Therapie. 2020;75:157-60.
24. Bharadwaj PR, Bates KA, Porter T, et al. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases. Transl Psychiatry. 2013;3:e332.
25. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712.
26. WHO-EURO. Repurposing of medicines - the underrated champion of sustainable innovation: policy brief. Available from: https://apps.who.int/iris/handle/10665/342567 [Last accessed on 7 Apr 2023].
27. Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018;175:168-80.
28. Conour J. Why method of treatment patents for repurposed drugs are worth the investment. Available from: https://www.jdsupra.com/legalnews/why-method-of-treatment-patents-for-92813/ [Last accessed on 7 Apr 2023].
29. Verbaanderd C, Rooman I, Huys I. Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research. Trials. 2021;22:322.
30. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649-51.
31. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128-40.
32. U.S. Department of Health and Human Services; Food and Drug Administration. Best practices in developing proprietary names for human prescription drug products guidance for industry. Available from: https://www.fda.gov/media/88496/download [Last accessed on 7 Apr 2023].
33. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735-46.
34. Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health. 2012;48:902-6.
35. European Medicines Agency. Paediatric-use marketing authorisations. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/paediatric-medicines/paediatric-use-marketing-authorisations [Last accessed on 7 Apr 2023].
36. Hachem M, Bonamonte D, Diociaiuti A, Mantuano M, Teruzzi C. Cost-utility analysis of propranolol versus corticosteroids in the treatment of proliferating infantile hemangioma in Italy. PharmacoEcon Ital Res Artic. 2015:17.
37. Jadeja N. The role of IP in strategies for repurposing medicines. Available from: http://www.pinsentmasons.com/out-law/analysis/the-role-of-ip-strategies-repurposing-medicines [Last accessed on 7 Apr 2023].
38. Veldman A, Richter E, Hacker C, Fischer D. The use of off-label medications in newborn infants despite an approved alternative being available-results of a national survey. Pharmacy (Basel). 2022;10:19.
39. Ahmed F, Fattani MT, Ali SR, Enam RN. Strengthening the bridge between academic and the industry through the academia-industry collaboration plan design model. Front Psychol. 2022;13:875940.
40. European Commission. Commission Expert Group on safe and timely access to medicines for patients (“STAMP”). Available from: https://health.ec.europa.eu/medicinal-products/pharmaceutical-committee-veterinary-pharmaceutical-committee-and-expert-groups/commission-expert-group-safe-and-timely-access-medicines-patients-stamp_en [Last accessed on 7 Apr 2023].
41. European Medicines Agency. Proposal for a framework to support not-for-profit organisations and academia (institutions and individuals) in drug repurposing. Available from: https://www.ema.europa.eu/en/documents/other/question-answers-repurposing-pilot-project-proposal-framework-support-not-profit-organisations_en.pdf [Last accessed on 7 Apr 2023].
42. European Medicines Agency. Building a European innovation platform for the repurposing of medicinal products. Available from: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2021-disease-04-02 [Last accessed on 7 Apr 2023].
43. Hechtelt Jonker A, Hivert V, Gabaldo M, et al. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook. Nat Rev Drug Discov. 2020;19:495-6.
44. Deplanque D, Fetro C, Ferry A, et al. Drug repurposing: from the discovery of a useful pharmacological effect to making the treatment available to the patient. Therapie. 2023;78:10-8.
45. Innovative health initiative. Available from: https://www.ihi.europa.eu/about-ihi [Last accessed on 7 Apr 2023].
